26 Jul Excision BioTherapeutics
Daniel Dornbusch, CEO
Oct. 13 | 11:30am | Oxford Biomedica Ballroom
San Francisco, CA
Excision BioTherapeutics is a biotechnology company developing CRISPR-based therapies as potential cures for viral infectious diseases. Excision unites next-generation CRISPR nucleases with a novel gene editing approach and has become the first and only company in history to cure HIV with a therapeutic in an animal model. EBT-101, the company’s lead program intended to cure HIV with a single IV infusion, is being evaluated in clinical trials. Excision’s pipeline includes one-time potential cures for herpes virus, JC virus, which causes PML, and hepatitis B virus. The company’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley.